Boston Scientific announces results for second quarter 2026

Rhea-AI Summary

Boston Scientific (NYSE: BSX) reported Q2 2026 net sales of $5.442 billion, up 7.5% reported and 7.0% operational and organic versus Q2 2025. GAAP EPS was $0.61 (vs. $0.53), and adjusted EPS reached $0.86, above the $0.82–$0.84 guidance range.

MedSurg sales grew 5.9% and Cardiovascular 8.3% reported. By region, U.S. rose 6.2%, EMEA 6.1%, APAC 11.2% and LACA 22.4% reported. Operating income increased to $1.178 billion from $819 million, while litigation-related net charges were $76 million.

The company completed a $2 billion accelerated share repurchase (~40 million shares) and invested $1.5 billion for a 34% stake in MiRus and an exclusive option on its TAVR business. Boston Scientific also highlighted positive clinical data for FARAPULSE and SEISMIQ technologies and received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter. Full-year 2026 guidance is for net sales growth of 5.5–6.5% reported and adjusted EPS of $3.28–$3.32; Q3 2026 net sales growth is guided to 3–5% with adjusted EPS of $0.80–$0.82.

Positive

• Net sales $5.442B, up 7.5% reported and 7.0% organic YoY in Q2 2026
• GAAP EPS $0.61 and adjusted EPS $0.86, above $0.82–$0.84 guidance
• Operating income $1.178B vs. $819M, driven by higher gross profit
• APAC +11.2% and LACA +22.4% reported net sales growth
• $2B accelerated share repurchase completed, ~40M shares retired
• $1.5B investment for 34% MiRus stake and TAVR option
• Full-year 2026 adjusted EPS guidance $3.28–$3.32

Negative

• Q3 2026 net sales growth guided to 3–5%, below Q2 7.5%
• Full-year 2026 net sales growth guided to 5.5–6.5%, below Q2 run-rate
• Q2 2026 litigation-related net charges of $76M
• Selling, general and administrative expenses rose to $1.803B from $1.716B
• Urology business grew only 1.1% reported in Q2 2026

Market Reaction – BSX

+8.34% $49.90

15m delay

+8.34% Vs previous close

$49.90 Last Price

$46.40 $50.30 Day Range

$73.28B Market Cap

0.0x Rel. Volume

Following this news, BSX has gained 8.34%, reflecting a notable positive market reaction. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $49.90.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The tag-specific earnings record averaged -1.17% across five events, adding a mixed-response lens to...

Analysis

The tag-specific earnings record averaged -1.17% across five events, adding a mixed-response lens to this quarter’s results. Net Buying by insiders was supportive context, while forward guidance and investigational-device execution warranted monitoring.

Key Figures

Net Sales: $5.442 billion Reported Sales Growth: 7.5% Adjusted EPS: $0.86 +5 more

8 metrics

Net Sales $5.442 billion Q2 2026

Reported Sales Growth 7.5% Q2 2026 versus prior-year period

Adjusted EPS $0.86 Q2 2026 versus guidance of $0.82 to $0.84

Full-Year Organic Sales Guidance 5 to 6% 2026

Full-Year Adjusted EPS Guidance $3.28 to $3.32 2026

Accelerated Share Repurchase $2 billion Completed in Q2 2026

MiRus Investment $1.5 billion Approximately 34% equity stake

510(k) Clearance 510(k) TruSelect 2.6 Microcatheter

Previous Earnings Reports

5 past events · Latest: May 06 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	First-quarter results	Positive	+1.0%	Penumbra reported quarterly revenue growth and maintained acquisition-related earnings-call restrictions.
Apr 22	First-quarter earnings	Positive	+9.0%	BSX reported sales growth, higher EPS, segment expansion, and multiple product developments.
Feb 25	Full-year results	Positive	-2.2%	Penumbra reported full-year revenue and margin growth while withholding 2026 guidance.
Feb 04	Fourth-quarter earnings	Positive	-17.6%	BSX reported quarterly growth and issued 2026 guidance alongside acquisition announcements.
Oct 22	Third-quarter results	Positive	+4.0%	BSX reported strong quarterly growth, above-guidance EPS, and updated annual guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings reactions were mixed, with three aligned events, two divergences, and an average move of -1.17%.

Key Terms

adjusted eps, accelerated share repurchase, 510(k) clearance, investigational device exemption, +2 more

6 terms

adjusted eps financial

"achieved adjusted EPS of $0.86 for the period"

Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.

accelerated share repurchase financial

"Completed the previously announced $2 billion accelerated share repurchase program"

An accelerated share repurchase is a deal where a company hires a bank to buy back a large block of its own stock immediately on the open market, with the bank later settling the exact number of shares over time. For investors it matters because the immediate reduction in shares outstanding can raise per‑share earnings and often supports the stock price, but it also uses company cash or borrowing and can change liquidity and future growth funding.

510(k) clearance regulatory

"Received U.S. Food and Drug Administration 510(k) clearance"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

investigational device exemption regulatory

"FRACTURE Investigational Device Exemption trial"

An investigational device exemption (IDE) is a regulatory permission that allows a medical device maker to test an unapproved device in people so the device’s safety and effectiveness can be studied. For investors, an IDE matters because it marks a formal step toward regulatory approval—like getting a temporary test-drive permit—and influences clinical cost, timelines, and the likelihood a device will reach the market and generate revenue.

pulsed field ablation medical

"FARAPULSE™ Pulsed Field Ablation (PFA)"

Pulsed field ablation is a heart procedure that uses very short, high-voltage electrical pulses to selectively disrupt abnormal heart tissue that causes irregular rhythms, rather than heating or freezing it. For investors, it matters because this approach can shorten procedure times, reduce damage to nearby structures, and potentially lower complication rates compared with traditional thermal methods, which can affect device adoption, hospital costs, and market demand for treatment tools.

intravascular lithotripsy medical

"SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter"

A catheter-based procedure that uses short pulses of sonic pressure waves delivered inside blood vessels to crack and soften hard calcium deposits that narrow arteries, much like using controlled pebbles to chip away a stubborn rock clog in a pipe. Investors care because the technology can make minimally invasive artery treatments safer and more effective, potentially increasing procedure volumes, device sales, hospital adoption and reimbursement, which affect medical-device company revenues and healthcare costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational¹ and organic² basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted³ EPS of $0.86 for the period, compared to $0.75 a year ago.

"Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."

Second quarter financial results and recent developments:

• Reported net sales of $5.442 billion, representing an increase of 7.5 percent on a reported basis, compared to the company's guidance range of 5.5 to 7.5 percent; and 7.0 percent on an operational and organic basis, compared to the company's guidance range of 5 to 7 percent, all compared to the prior year period.

• Reported GAAP net income attributable to Boston Scientific common stockholders of $0.61 per share, and achieved adjusted EPS of $0.86 per share, compared to the guidance range of $0.82 to $0.84 per share.

• Achieved the following net sales growth in each reportable segment, compared to the prior year period:
  • MedSurg: 5.9 percent reported, 5.4 percent operational and organic
  • Cardiovascular: 8.3 percent reported, 7.8 percent operational and organic

• Achieved the following net sales growth in each region, compared to the prior year period:
  • United States (U.S.): 6.2 percent reported and operational
  • Europe, Middle East and Africa (EMEA): 6.1 percent reported and 4.2 percent operational
  • Asia-Pacific (APAC): 11.2 percent reported and operational
  • Latin America and Canada (LACA): 22.4 percent reported and 16.2 percent operational

• Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.

• Invested $1.5 billion in MiRus LLC, which is developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, in return for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business.⁴

• Presented late-breaking findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints with the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter, demonstrating high rates of freedom from major adverse cardiac events at 30 days as well as procedural success in patients with severely calcified coronary artery disease.⁴

• Announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026 including:
  • The AVANT GUARD study of FARAPULSE™ Pulsed Field Ablation (PFA) for the treatment of persistent atrial fibrillation (AF) in patients who had not previously been treated for their condition. Data met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.
  • The ELEVATE-PF feasibility study of the FARAFLEX™ Mapping and PFA Catheter — a novel large focal, high-density map-and-ablate catheter — in patients with paroxysmal and persistent AF. The trial demonstrated strong lesion durability validated by cardiac remapping, with no reported cases of pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke.⁴ 

• Commenced enrollment in the pivotal FARADIGM clinical trial to evaluate the safety and effectiveness of the FARAFLEX Mapping and PFA Catheter for treating patients with paroxysmal and persistent AF.⁴ 

• Received U.S. Food and Drug Administration 510(k) clearance for the TruSelect™ 2.6 Microcatheter, expanding Boston Scientific's embolization portfolio with a device designed to provide physicians with a single solution for navigation and efficient embolic delivery during minimally invasive procedures.

1.	Operational net sales growth excludes the impact of foreign currency fluctuations.
2.	Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
3.	Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.
4.	The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Net sales for the second quarter by business and region:

					Increase/(Decrease)
		Three Months Ended                     June 30,			Reported Basis		Impact of Foreign Currency Fluctuations		Operational  Basis		Impact of Certain Acquisitions /Divestitures		Organic Basis
(in millions)		2026	2025
	Endoscopy	$      793	$      737		7.6 %		(0.7) %		7.0 %		— %		7.0 %
	Urology	684	676		1.1 %		(0.3) %		0.8 %		— %		0.8 %
	Neuromodulation	341	303		12.7 %		(0.6) %		12.2 %		— %		12.2 %
	MedSurg	1,818	1,716		5.9 %		(0.5) %		5.4 %		— %		5.4 %
	Cardiovascular	3,624	3,345		8.3 %		(0.6) %		7.8 %		— %		7.8 %
Net Sales		$    5,442	$    5,061		7.5 %		(0.5) %		7.0 %		— %		7.0 %
									Increase/(Decrease)
					Three Months Ended                     June 30,				Reported Basis		Impact of Foreign Currency Fluctuations		Operational  Basis
	(in millions)				2026		2025
	U.S.				$     3,426		$     3,224		6.2 %		— %		6.2 %
	EMEA				932		878		6.1 %		(1.9) %		4.2 %
	APAC				878		790		11.2 %		(0.0) %		11.2 %
	LACA				206		169		22.4 %		(6.2) %		16.2 %
	Net Sales				$    5,442		$    5,061		7.5 %		(0.5) %		7.0 %
	Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.
	Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of certain acquisitions/divestitures are not            prepared in accordance with U.S. GAAP.

Guidance for Full Year and Third Quarter 2026

The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to 6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.

The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to 5 percent on a reported and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.

The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the third quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Use of Non-GAAP Financial Information

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

CONTACT:
‌	Media:	Chanel Hastings		Investors:	Lauren Tengler
		508-382-0288 (office)			508-683-4479 (office)
		Media Relations			Investor Relations
		Boston Scientific Corporation			Boston Scientific Corporation
		chanel.hastings@bsci.com			BSXInvestorRelations@bsci.com

 

BOSTON SCIENTIFIC CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
	Three Months Ended                     June 30,		‌	Six Months Ended                     June 30,
(in millions, except per share data)	2026	2025		2026	2025
Net sales	$      5,442	$      5,061		$     10,646	$      9,724
Cost of products sold (excluding amortization expense)	1,594	1,637		3,184	3,090
Gross profit	3,848	3,424		7,462	6,633
Operating expenses:
Selling, general and administrative expenses	1,803	1,716		3,583	3,312
Research and development expenses	554	526		1,069	969
Royalty expense	12	14		24	28
Amortization expense	233	225		466	444
Intangible asset impairment charges	—	46		—	46
Contingent consideration net expense (benefit)	(16)	(5)		(46)	0
Restructuring net charges (credits)	8	83		11	93
Litigation-related net charges (credits)	76	—		76	—
	2,670	2,605		5,183	4,894
Operating income (loss)	1,178	819		2,279	1,740
Other income (expense):
Interest expense	(96)	(90)		(186)	(172)
Other, net	(23)	213		129	179
Income (loss) before income taxes	1,060	941		2,222	1,746
Income tax expense (benefit)	155	146		(21)	279
Net income (loss)	905	795		2,243	1,467
Net income (loss) attributable to noncontrolling interests	(2)	(2)		(4)	(4)
Net income (loss) attributable to Boston Scientific common stockholders	$        907	$        797		$      2,247	$      1,471
Net income (loss) per common share - basic	$        0.62	$        0.54		$        1.52	$        0.99
Net income (loss) per common share - diluted	$        0.61	$        0.53		$        1.51	$        0.98
Weighted-average shares outstanding
Basic	1,470.2	1,479.9		1,477.6	1,478.5
Diluted	1,474.8	1,493.5		1,484.9	1,493.3
Amounts may not add due to rounding.

 

BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS (Unaudited)
	Three Months Ended June 30, 2026
(in millions, except per share data)	Gross Profit	Operating Expenses	Operating Income (Loss)	Other Income (Expense)	Income (Loss) Before Income Taxes	Net Income (Loss)	Net Income (Loss) Attributable to Noncontrolling Interests	Net Income (Loss) Attributable to Boston Scientific Common Stockholders	Impact per Share
Reported	$   3,848	$   2,670	$   1,178	$    (118)	$   1,060	$     905	$           (2)	$          907	$   0.61
Non-GAAP adjustments:
Amortization expense	—	(233)	233	—	233	206	2	203	0.14
Acquisition/divestiture-related net charges/credits	30	(61)	91	1	92	72	—	72	0.05
Restructuring and restructuring-related net charges/credits	25	(16)	42	—	42	37	—	37	0.02
Litigation-related net charges/credits	—	(76)	76	—	76	60	—	60	0.04
Investment portfolio net losses/gains and impairments	—	—	—	(2)	(2)	(2)	—	(2)	(0.00)
EU MDR implementation costs	4	(3)	7	—	7	6	—	6	0.00
IEEPA tariff refund	(83)	—	(83)	—	(83)	(77)	—	(77)	(0.05)
Deferred tax expenses/benefits	—	—	—	—	—	70	—	70	0.05
Adjusted	$   3,824	$   2,281	$   1,543	$    (120)	$   1,423	$   1,275	$            1	$        1,275	$   0.86
	Three Months Ended June 30, 2025
(in millions, except per share data)	Gross Profit	Operating Expenses	Operating Income (Loss)	Other Income (Expense)	Income (Loss) Before Income Taxes	Net Income (Loss)	Net Income (Loss) Attributable to Noncontrolling Interests	Net Income (Loss) Attributable to Boston Scientific Common Stockholders	Impact per Share
Reported	$   3,424	$   2,605	$     819	$     122	$     941	$     795	$           (2)	$          797	$   0.53
Non-GAAP adjustments:
Amortization expense	—	(225)	225	—	225	193	2	191	0.13
Goodwill and other intangible asset impairment charges	—	(46)	46	—	46	37	—	37	0.02
Acquisition/divestiture-related net charges/credits	46	(92)	138	(230)	(92)	(92)	—	(92)	(0.06)
Restructuring and restructuring-related net charges/credits	37	(124)	161	—	161	142	—	142	0.10
Investment portfolio net losses/gains and impairments	—	—	—	(2)	(2)	(2)	—	(2)	(0.00)
EU MDR implementation costs	7	(3)	10	—	10	9	—	9	0.01
Deferred tax expenses/benefits	—	—	—	—	—	45	—	45	0.03
Discrete tax items	—	—	—	—	—	0	—	0	0.00
Adjusted	$   3,514	$   2,114	$   1,399	$    (110)	$   1,289	$   1,127	$            0	$        1,127	$   0.75
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.
Amounts may not add due to rounding.
BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS (Unaudited)
	Six Months Ended June 30, 2026
(in millions, except per share data)	Gross Profit	Operating Expenses	Operating Income (Loss)	Other Income (Expense)	Income (Loss) Before Income Taxes	Net Income (Loss)	Net Income (Loss) Attributable to Noncontrolling Interests	Net Income (Loss) Attributable to Boston Scientific Common Stockholders	Impact per Share
Reported	$   7,462	$   5,183	$   2,279	$     (57)	$   2,222	$   2,243	$           (4)	$        2,247	$   1.51
Non-GAAP adjustments:
Amortization expense	—	(466)	466	—	466	410	5	406	0.27
Acquisition/divestiture-related net charges/credits	57	(118)	175	(36)	139	103	—	103	0.07
Restructuring and restructuring-related net charges/credits	47	(29)	77	—	77	69	—	69	0.05
Litigation-related net charges/credits	—	(76)	76	—	76	60	—	60	0.04
Investment portfolio net losses/gains and impairments	—	—	—	(139)	(139)	(106)	—	(106)	(0.07)
EU MDR implementation costs	9	(5)	14	—	14	12	—	12	0.01
IEEPA tariff refund	(83)	—	(83)	—	(83)	(77)	—	(77)	(0.05)
Deferred tax expenses/benefits	—	—	—	—	—	(250)	—	(250)	(0.17)
Adjusted	$   7,492	$   4,490	$   3,002	$    (232)	$   2,771	$   2,465	$            1	$        2,464	$   1.66
	Six Months Ended June 30, 2025
(in millions, except per share data)	Gross Profit	Operating Expenses	Operating Income (Loss)	Other Income (Expense)	Income (Loss) Before Income Taxes	Net Income (Loss)	Net Income (Loss) Attributable to Noncontrolling Interests	Net Income (Loss) Attributable to Boston Scientific Common Stockholders	Impact per Share
Reported	$   6,633	$   4,894	$   1,740	$       6	$   1,746	$   1,467	$           (4)	$        1,471	$   0.98
Non-GAAP adjustments:
Amortization expense	—	(444)	444	—	444	383	4	378	0.25
Goodwill and other intangible asset impairment charges	—	(46)	46	—	46	37	—	37	0.02
Acquisition/divestiture-related net charges/credits	136	(150)	286	(229)	57	61	—	61	0.04
Restructuring and restructuring-related net charges/credits	61	(149)	210	—	210	184	—	184	0.12
Investment portfolio net losses/gains and impairments	—	—	—	6	6	5	—	5	0.00
EU MDR implementation costs	15	(7)	23	—	23	19	—	19	0.01
Deferred tax expenses/benefits	—	—	—	—	—	91	—	91	0.06
Discrete tax items	—	—	—	—	—	0	—	0	0.00
Adjusted	$   6,846	$   4,097	$   2,749	$    (216)	$   2,533	$   2,249	$            1	$        2,248	$   1.51
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.
Amounts may not add due to rounding.

 

BOSTON SCIENTIFIC CORPORATION Q3 and FY 2026 GUIDANCE RECONCILIATIONS (Unaudited)
Net Sales				‌
	Q3 2026 Estimate				Full Year 2026 Estimate
	(Low)	(High)			(Low)	(High)
Reported growth	3.0 %	5.0 %			5.5 %	6.5 %
Impact of foreign currency fluctuations	— %	— %			(0.5) %	(0.5) %
Operational growth	3.0 %	5.0 %			5.0 %	6.0 %
Impact of certain acquisitions/divestitures	— %	— %			— %	— %
Organic growth	3.0 %	5.0 %			5.0 %	6.0 %

Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits), discrete tax items and other charges (credits) as appropriate. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." In addition to the explanation below, please refer to Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type, since our most recent Annual Report on Form 10-K, that management excluded as part of these non-GAAP financial measures as well as the reason for excluding each item:

• Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations. In addition, we may incur certain charges such as severance and other compensation-related charges, fixed asset write-offs, contract cancellations, facility shutdown costs, and inventory write-downs associated with discontinuations of significant product lines. These restructuring plans and activities are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.
  
  
• Deferred tax expenses (benefits) - These amounts represent significant non-cash tax benefits arising from internal reorganizations or intra-entity asset transfers. The deferred tax effects related to the establishment and subsequent reversal of net deferred tax assets are excluded from management's assessment of operating performance used for making operating decisions and assessing performance.
  
  
• IEEPA tariff refund - This amount relates to the benefit recognized in connection with the recovery of previously incurred tariffs imposed under the International Emergency Economic Powers Act (IEEPA) recognized in Cost of products sold within our unaudited consolidated statements of operations. This amount is excluded from management's assessment of operating performance used for making operating decisions and assessing performance.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales reported on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-results-for-second-quarter-2026-302837127.html

SOURCE Boston Scientific Corporation

FAQ

How did Boston Scientific (BSX) perform financially in Q2 2026?

Boston Scientific reported Q2 2026 net sales of $5.442 billion, up 7.5% reported year over year. According to Boston Scientific, GAAP EPS was $0.61 and adjusted EPS was $0.86, exceeding the company’s $0.82–$0.84 guidance range for the quarter.

What are Boston Scientific’s 2026 full-year guidance targets for BSX?

Boston Scientific guides 2026 full-year net sales growth to 5.5–6.5% reported and 5–6% organic. According to Boston Scientific, full-year adjusted EPS is expected between $3.28 and $3.32, excluding specified charges and credits that are not forecast on a GAAP basis.

What guidance did Boston Scientific (BSX) give for Q3 2026 results?

For Q3 2026, Boston Scientific expects net sales growth of 3–5% on a reported and organic basis. According to Boston Scientific, adjusted EPS for the quarter is projected at $0.80–$0.82, excluding certain items such as acquisition-related and restructuring charges.

How did Boston Scientific’s MedSurg and Cardiovascular segments perform in Q2 2026?

In Q2 2026, MedSurg sales grew 5.9% reported and Cardiovascular sales grew 8.3% reported year over year. According to Boston Scientific, MedSurg reached $1.818 billion in net sales and Cardiovascular reached $3.624 billion during the quarter.

What major capital actions did Boston Scientific (BSX) take in Q2 2026?

Boston Scientific completed a $2 billion accelerated share repurchase, retiring about 40 million shares. According to Boston Scientific, the company also invested $1.5 billion in MiRus for a 34% stake and an exclusive option to acquire the MiRus TAVR business.

Which regions drove Boston Scientific’s (BSX) revenue growth in Q2 2026?

Asia-Pacific and Latin America/Canada were key growth drivers in Q2 2026. According to Boston Scientific, APAC net sales increased 11.2% reported and LACA increased 22.4% reported year over year, outpacing the consolidated 7.5% reported growth rate.

What clinical and regulatory milestones did Boston Scientific highlight with its Q2 2026 earnings?

Boston Scientific reported positive late-breaking data for its FARAPULSE PFA and SEISMIQ lithotripsy technologies in multiple trials. According to Boston Scientific, the company also received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter, expanding its embolization product portfolio.